--Street Color: Core Scientific Terminates Merger Deal With CoreWeave-February 2024-www.financetom.com

--Street Color: Core Scientific Terminates Merger Deal With CoreWeave

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Street Color: Core Scientific Terminates Merger Deal With CoreWeave

Oct 30, 2025 8:19 AM

10:38 AM EDT, 10/30/2025 (MT Newswires) --

Price: 20.35, Change: -0.43, Percent Change: -2.05

Previous page： Newmont lays off nearly a dozen managers, plans to merger businesses, Bloomberg News reports Next page： --Newmont Cuts Nearly a Dozen Managers, Bloomberg Reports

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Newmont lays off nearly a dozen managers, plans to merger businesses, Bloomberg News reports

Dec 9, 2024

Dec 9 (Reuters) - Gold miner Newmont ( NEM ) let go of nearly a dozen managers, including a member of its executive team, as part of a corporate overhaul, Bloomberg News reported on Monday, citing people familiar with the matter. The report said that the company had initiated plans to dismiss one executive and at least 10 senior managers,...

--Newmont Cuts Nearly a Dozen Managers, Bloomberg Reports

Dec 9, 2024

01:56 PM EST, 12/09/2024 (MT Newswires) -- Price: 42.07, Change: +0.96, Percent Change: +2.34 ...

Market Chatter: Italy Ends Probe Into Meta Platforms Irish Unit Executives on Alleged Tax Evasion

Dec 9, 2024

01:59 PM EST, 12/09/2024 (MT Newswires) -- A probe by Italian authorities into alleged tax evasion of 887.6 million euros ($937.93 million) by two executives from Meta Platforms' ( META ) Irish unit concluded, paving the way for a request for trial, Reuters reported Monday, citing the Milan prosecutor's office. Meta has 60 days to respond to the tax authority's...

Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study

Dec 9, 2024

02:02 PM EST, 12/09/2024 (MT Newswires) -- Affimed ( AFMD ) said Monday that AFM28 showed promising efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study. The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients,...